Drug/Small Molecule:
mitiglinide

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this drug/small molecule. To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • KAD-1229
  • Mitiglinide calcium hydrate
  • mitiglinide
Trade Names
  • Glufast
Brand Mixture Names

PharmGKB Accession Id:
PA164748124

Description

Mitiglinide is a drug for the treatment of type 2 diabetes .Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells.

Source: Drug Bank

Indication

For the treatment of type 2 diabetes.

Source: Drug Bank

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.

Source: Drug Bank

Pharmacology

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs. It is approved for use in Japan but has not yet gained FDA approval.

Source: Drug Bank

Chemical Properties

Chemical Formula

C19H25NO3

Source: Drug Bank

Isomeric SMILES

C1CC[C@H]2CN(C[C@H]2C1)C(=O)C[C@H](CC3=CC=CC=C3)C(=O)O

Source: Drug Bank

OC(=O)C(CC(=O)N1CC2CCCCC2C1)CC1=CC=CC=C1

Source: Drug Bank

Canonical SMILES

OC(=O)C(CC(=O)N1CC2CCCCC2C1)CC1=CC=CC=C1

Source: Drug Bank

Average Molecular Weight

315.4067

Source: Drug Bank

Monoisotopic Molecular Weight

315.183443671

Source: Drug Bank

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB01252
KEGG Drug:
D01854
PubChem Compound:
3047758
PubChem Substance:
10053765
46506527
ChemSpider:
2310083
Therapeutic Targets Database:
DAP000917

Clinical Trials

These are trials that mention mitiglinide and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.